NCT Number: NCT00403715
Study of INS365 Ophthalmic Solution in Subjects With Dry Eye Disease
The purpose of this trial is to compare the effectiveness and safety of INS365 Ophthalmic Solution with Placebo when applied topically in subjects with dry eye disease.
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- best corrected visual acuity in both eyes of at least +0.7
- six-month documented history of dry eye disease
- at least mild severity in 2 of the 4 dry eye symptoms
- unanesthetized Schirmer score of less than or equal to 7mm
- corneal fluorescein staining of greater than or equal to 4 (out of 15)
Exclusion criteria
- nasally stimulated Schirmer score of less than 3mm in subjects with an initial Schirmer score of 0mm
- ongoing contact lens wear
- current topical ophthalmic medication use
Treatment and study plan
Primary outcomes
-
change in dry eye testing measures and symptoms
Secondary outcomes
-
change in dry eye testing measures and symptoms
Sponsors and collaborators
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Registry information
Official study title
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Subjects With Dry Eye Disease
Important dates
- Study start
- 2001
- Primary completion
- 2002
- Study completion
- 2002
- First posted
- Nov 27, 2006
- Registry last updated
- Nov 29, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
An Evaluation of the Safety and Tolerability of Ocular Lubricants
NCT07238699
Dry Eye Disease, Dry Eye Syndromes
Sydney, New South Wales, Australia
View Trial DetailsA Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
NCT07025811
Dry Eye Disease, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsA Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT07128628
Dry Eye Disease, Dry Eye Syndromes
Phoenix, Arizona, United States
View Trial DetailsEvaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT07264517
Autoimmune Diseases, Dry Eye Disease
Glendale, California, United States
View Trial Details